The Weekly Roundup: Pricing Woes (5.4.18)
When it comes to assigning blame for drug pricing, there’s plenty of it go around. We’ve seen an uptick in campaigns like this one defending the pharmaceutical industry, and this one defending PBMs. Many of our members have been active in developing and supporting legislation on the federal and state levels to shed some light on pricing practices. It’s an uphill battle, but now one that has another general: class-action attorney Steve Berman. Berman has a long history of besting corporate Goliaths and he is painting Big Pharma with an almost operatic brush. Just as the U.S. Racketeering and Corrupt Organizations Act [RICO] was the cudgel used to take down the mob, it is believed the statute could also be used to break open pharma’s stranglehold on pricing. It’s already being used as the basis for a class action suit that pulls wholesalers into the mix for increases to health costs attributable to the opioid epidemic. On another front, remarks by FDA Commissioner Scott Gottlieb to the Food and Drug Law Institute suggested that removing safe harbor provisions for drug rebates under federal anti-kickback law could “help restore some semblance of reality to the relationship between list and negotiated prices…” Meanwhile, PhRMA, the trade group that represents pharmaceutical manufacturers, broke its own quarterly spending record this year: nearly $10 million on lobbyists. Part of that spending was aimed at defeating a law that would make them responsible for an estimated 70 percent of seniors’ “donut hole” costs. The law providing for the additional hit to manufacturers goes into effect in 2019.
Here are a few other stories that might be of interest:
- It’s not easy out there—and CVS isn’t helping.
- Gear up for summer. The CDC is warning that tick- and mosquito-borne diseases are skyrocketing. (Need help educating your patients on protection? Download our free Smart-Take on Lyme Disease to use in your store.)
- Soon coming to a counter near you. Somna Therapeutics’ prescription reflux product has recently been approved by the FDA for OTC use.
- Yuma and you: Check out four things pharmacists need to know about E. coli outbreaks.
[Editor’s note:] Our inboxes are stuffed with newsletters and our coffee tables stacked with magazines and industry digests. I’m sure yours are, too. So we’ve decided to run a weekly sampling of interesting stories, issues coverage, and business ideas we come across each week. We hope you’ll share some of your favorites, too. Drop us a line at firstname.lastname@example.org.
Sign up now to receive the latest independent
pharmacy news, tips, and resources.
Nearly a quarter of women and just over five percent of men over 65 have osteoporosis of the femur or lumbar spine, putting them at a high risk of fracture. To help spread awareness of its risks and treatment, we've created another installation for our Smart-Take...
The times they are a-changin’. Compounds found in cannabis are rapidly gaining appreciation from the mainstream medical community. Last week, the FDA announced its support of a cannabidiol compound for its potential to treat seizure disorders. The treatment would be marketed under the name Epidiolex by...